Development of a dual inhibitor of pan-RAF and VEGFR2 for the treatment of metastatic colorectal cancer with mutant K-RAS

被引：0
|
作者：
Hong, Sungpyo
Choi, Young-Il
Choi, Jihye
Kim, Wonyoung
Kwon, Ho-Seok
Park, Yong Bin
Ki, Min-Hyo
Shin, Hee Jong
Lee, Michael
Ahn, Soon Kil
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-3782
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3782
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Factors influencing the detection of mutant K-ras in the serum of patients with colorectal cancer
    Ward, R
    Sheehan, C
    Norrie, M
    Applegate, T
    Fuery, C
    Impey, H
    Hawkins, N
    Todd, A
    CIRCULATING NUCLEIC ACIDS IN PLASMA OR SERUM, 2000, 906 : 17 - 18
  • [22] RAF KINASE INHIBITOR PROTEIN (RKIP) IS NOT A PREDICTIVE FACTOR IN PATIENTS WITH K-RAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH CETUXIMAB OR PANITUMUMAB
    Saletti, P.
    Molinari, F.
    Zlobec, I
    Lugli, A.
    De Dosso, S.
    Tornillo, L.
    Terracciano, L.
    Mazzucchelli, L.
    Frattini, M.
    ANNALS OF ONCOLOGY, 2009, 20 : 21 - 21
  • [23] A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer
    Cheng, Ying
    Wang, Xingkai
    Xia, Xiangying
    Zhang, Wei
    Tian, Hongqi
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (02) : 586 - 596
  • [24] Future Solutions for Patients with Metastatic Colorectal Cancer Positive for K-RAS Mutations
    Capareli-Azevedo, Fernanda
    Riechelmann, Rachel P.
    Hoff, Paulo M.
    CURRENT COLORECTAL CANCER REPORTS, 2011, 7 (04) : 275 - 280
  • [25] Targeting tumor microenvironment for treatment of K-ras mutant lung cancer
    Caetano, Mauricio da Silva
    Chang, Seon Hee
    Cumpian, Amber M.
    Daliri, Soudabeh
    De La Garza, Maria Miguelina
    Ochoa, Cesar E.
    Dong, Chen
    Moghaddam, Seyed Javad
    MOLECULAR CANCER RESEARCH, 2014, 12
  • [26] Timing of testing for K-ras mutational status in metastatic colorectal cancer (mCRC).
    Corral, Mitra
    Sotak, Michelle
    Chastek, Benjamin
    Penrod, John R.
    Cairns, Jessica
    Williams, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [27] Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
    Vincenzi, Bruno
    Cremolini, Chiara
    Sartore-Bianchi, Andrea
    Russo, Antonio
    Mannavola, Francesco
    Perrone, Giuseppe
    Pantano, Francesco
    Loupakis, Fotios
    Rossini, Daniele
    Ongaro, Elena
    Bonazzina, Erica
    Dell'Aquila, Emanuela
    Imperatori, Marco
    Zoccoli, Alice
    Bronte, Giuseppe
    De Maglio, Giovanna
    Fontanini, Gabriella
    Natoli, Clara
    Falcone, Alfredo
    Santini, Daniele
    Onetti-Muda, Andrea
    Siena, Salvatore
    Tonini, Giuseppe
    Aprile, Giuseppe
    ONCOTARGET, 2015, 6 (31) : 31604 - 31612
  • [28] Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer
    Elsabah, Mahmoud Tag
    Adel, Iman
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2013, 25 (01) : 51 - 56
  • [29] Impact of K-RAS mutation status on disease behavior and treatment outcome in metastatic colorectal cancer patients
    Rasmy, A.
    Fayed, A.
    Fouad, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] A selective and potent pan-RAF inhibitor, HM95573 exhibits high therapeutic potential as a next-generation RAF inhibitor by direct inhibition of RAF kinase activity in BRAF or RAS mutant cancers
    Namgoong, G.
    Kim, S. H.
    Song, T. H.
    Bae, I. H.
    Ahn, Y. G.
    Lee, J. H.
    Choi, K.
    Lee, K. H.
    Kim, Y. H.
    Lee, Y. M.
    Suh, K. H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S127 - S127
12345